US Dollar vs MXN

Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

Regístrate

ALKS

Alkermes (ALKS)

Alkermes PLC

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ALKS

1 2 3 4 5 6 7 8 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
14/05/2024	15:30	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:ALKS	Alkermes PLC
14/05/2024	06:00	PR Newswire (US)	Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences	NASDAQ:ALKS	Alkermes PLC
02/05/2024	06:00	PR Newswire (US)	Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk	NASDAQ:ALKS	Alkermes PLC
01/05/2024	06:00	PR Newswire (US)	Alkermes plc Reports First Quarter 2024 Financial Results	NASDAQ:ALKS	Alkermes PLC
24/04/2024	06:00	PR Newswire (US)	Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1	NASDAQ:ALKS	Alkermes PLC
17/04/2024	15:00	PR Newswire (US)	Alkermes to Report First Quarter Financial Results on May 1, 2024	NASDAQ:ALKS	Alkermes PLC
09/04/2024	06:00	PR Newswire (US)	Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia	NASDAQ:ALKS	Alkermes PLC
08/04/2024	06:00	PR Newswire (US)	Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society	NASDAQ:ALKS	Alkermes PLC
07/03/2024	06:09	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALKS	Alkermes PLC
07/03/2024	06:00	PR Newswire (US)	Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors	NASDAQ:ALKS	Alkermes PLC
27/02/2024	15:09	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALKS	Alkermes PLC
21/02/2024	15:01	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:ALKS	Alkermes PLC
15/02/2024	06:00	PR Newswire (US)	Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024	NASDAQ:ALKS	Alkermes PLC
09/02/2024	17:19	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:ALKS	Alkermes PLC
08/02/2024	15:00	PR Newswire (US)	Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024	NASDAQ:ALKS	Alkermes PLC
03/01/2024	15:00	PR Newswire (US)	Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:ALKS	Alkermes PLC
03/01/2024	06:00	PR Newswire (US)	Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)	NASDAQ:ALKS	Alkermes PLC
14/12/2023	05:05	PR Newswire (US)	Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk	NASDAQ:ALKS	Alkermes PLC
01/12/2023	17:16	PR Newswire (US)	Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600	NASDAQ:ALKS	Alkermes PLC
21/11/2023	15:00	PR Newswire (US)	Alkermes to Participate in Two Upcoming Investor Conferences	NASDAQ:ALKS	Alkermes PLC
15/11/2023	06:00	PR Newswire (US)	Alkermes Completes Separation of Oncology Business	NASDAQ:ALKS	Alkermes PLC
07/11/2023	15:00	PR Newswire (US)	Alkermes to Participate in the Jefferies London Healthcare Conference	NASDAQ:ALKS	Alkermes PLC
31/10/2023	16:18	PR Newswire (US)	Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement	NASDAQ:ALKS	Alkermes PLC
25/10/2023	15:05	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ALKS	Alkermes PLC
25/10/2023	06:00	PR Newswire (US)	Alkermes plc Reports Third Quarter 2023 Financial Results	NASDAQ:ALKS	Alkermes PLC
23/10/2023	07:00	PR Newswire (US)	Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress	NASDAQ:ALKS	Alkermes PLC
18/10/2023	15:00	PR Newswire (US)	Alkermes to Report Third Quarter Financial Results on October 25, 2023	NASDAQ:ALKS	Alkermes PLC
10/10/2023	16:00	PR Newswire (US)	Mural Oncology to Host Investor Webcast on October 17	NASDAQ:ALKS	Alkermes PLC
10/10/2023	06:00	PR Newswire (US)	Alkermes to Present First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress	NASDAQ:ALKS	Alkermes PLC
11/09/2023	06:00	PR Newswire (US)	Alkermes Presents Clinical and Real-World Data at 36th Annual Psych Congress	NASDAQ:ALKS	Alkermes PLC

Showing the most relevant articles for your search:NASDAQ:ALKS

1 2 3 4 5 6 7 8 Próxima >

Eskay Mining (QX)

Helix Resources

Walker Lane Exploration (CE)

Viscogliosi Brothers Acq...

SG Issuer Societe Generale

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones